| Date | Time | Source | Headline | Symbol | Company |
| 04/30/2024 | 4:00AM | GlobeNewswire Inc. | U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab) | NASDAQ:ALVO | Alvontech |
| 04/30/2024 | 4:00AM | Business Wire | U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab) | NASDAQ:ALVO | Alvontech |
| 04/24/2024 | 4:00AM | GlobeNewswire Inc. | Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab) | NASDAQ:ALVO | Alvontech |
| 04/19/2024 | 6:10AM | GlobeNewswire Inc. | Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab) | NASDAQ:ALVO | Alvontech |
| 04/16/2024 | 5:43PM | Business Wire | Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab) | NASDAQ:ALVO | Alvontech |
| 04/16/2024 | 5:30PM | GlobeNewswire Inc. | Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab) | NASDAQ:ALVO | Alvontech |
| 04/03/2024 | 7:41AM | GlobeNewswire Inc. | Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024 | NASDAQ:ALVO | Alvontech |
| 03/22/2024 | 4:15PM | GlobeNewswire Inc. | Alvotech Announces Increase in Number of Own Shares | NASDAQ:ALVO | Alvontech |
| 03/20/2024 | 4:15PM | GlobeNewswire Inc. | Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update | NASDAQ:ALVO | Alvontech |
| 03/20/2024 | 7:17AM | IH Market News | U.S. Index Futures Trade Sideways Amid Anticipation of Fed’s Policy Update; Oil Prices Dip | NASDAQ:ALVO | Alvontech |
| 03/05/2024 | 4:00PM | GlobeNewswire Inc. | Alvotech Announces Webcast of Full Year 2023 Financial Results on March 21, 2024, at 8:00 am ET | NASDAQ:ALVO | Alvontech |
| 02/29/2024 | 4:05PM | GlobeNewswire Inc. | Alvotech Appoints Interim Chief Quality Officer | NASDAQ:ALVO | Alvontech |
| 02/26/2024 | 4:25AM | GlobeNewswire Inc. | Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purchase price of USD 16.41 (ISK 2,250) per Share | NASDAQ:ALVO | Alvontech |
| 02/23/2024 | 8:15PM | GlobeNewswire Inc. | Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira® | NASDAQ:ALVO | Alvontech |
| 02/23/2024 | 8:15PM | Business Wire | Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira® | NASDAQ:ALVO | Alvontech |
| 02/15/2024 | 6:30AM | GlobeNewswire Inc. | Alvotech Announces Expected Global Market Entry Dates for AVT04 Biosimilar to Stelara® (ustekinumab) | NASDAQ:ALVO | Alvontech |
| 01/29/2024 | 4:00AM | GlobeNewswire Inc. | Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva® | NASDAQ:ALVO | Alvontech |
| 01/19/2024 | 12:31PM | Dow Jones News | Alvotech Shares Climb After FDA Concludes Facility Inspection | NASDAQ:ALVO | Alvontech |
| 01/19/2024 | 11:30AM | GlobeNewswire Inc. | Alvotech Provides Update on Status of Biologics License Applications for AVT02 and AVT04 | NASDAQ:ALVO | Alvontech |
| 01/10/2024 | 3:30AM | GlobeNewswire Inc. | STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to Stelara | NASDAQ:ALVO | Alvontech |
| 01/03/2024 | 3:30AM | GlobeNewswire Inc. | Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT06 and Reference Product Eylea® (aflibercept) | NASDAQ:ALVO | Alvontech |
| 11/29/2023 | 4:00AM | GlobeNewswire Inc. | Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria® | NASDAQ:ALVO | Alvontech |
| 11/28/2023 | 4:15PM | GlobeNewswire Inc. | Alvotech Reports Financial Results for First Nine Months of 2023 and Provides a Business Update | NASDAQ:ALVO | Alvontech |
| 11/21/2023 | 8:00AM | GlobeNewswire Inc. | Alvotech to Report Financial Results for the First Nine Months of 2023 on November 28, 2023, and Host Business Update Conference Call on November 29, 2023, at 8:00 am ET | NASDAQ:ALVO | Alvontech |
| 11/14/2023 | 7:00AM | GlobeNewswire Inc. | Alvotech and JAMP Pharma Announce Receipt of Marketing Authorization for Jamteki™ (AVT04), the First Biosimilar of Stelara® (ustekinumab) | NASDAQ:ALVO | Alvontech |
| 11/10/2023 | 9:30AM | GlobeNewswire Inc. | STADA and Alvotech receive positive CHMP opinion for Europe’s first ustekinumab biosimilar to Stelara | NASDAQ:ALVO | Alvontech |
| 11/07/2023 | 8:00AM | GlobeNewswire Inc. | Alvotech to Present at the Jefferies 2023 London Healthcare Conference | NASDAQ:ALVO | Alvontech |
| 10/12/2023 | 4:00AM | GlobeNewswire Inc. | Alvotech Provides Update on Status of U.S. Biologics License Application for AVT04 | NASDAQ:ALVO | Alvontech |
| 10/03/2023 | 8:29AM | Business Wire | Kashiv BioSciences Enters into Exclusive Licensing Agreement with Alvotech for Development & Commercialization of a Proposed Biosimilar to Xolair® (omalizumab) | NASDAQ:ALVO | Alvontech |
| 10/03/2023 | 5:00AM | GlobeNewswire Inc. | Alvotech Enters into Exclusive Licensing Agreement with Kashiv BioSciences for Development and Commercialization of a Proposed Biosimilar to Xolair® (omalizumab) | NASDAQ:ALVO | Alvontech |